Related Experiment Videos
CD154 gene therapy for human B-cell malignancies
Davorka Messmer1, Thomas J Kipps
1Moores Cancer Center, University of California San Diego, 3855 Health Science Dr., Number 0820, La Jolla CA 92093-0820, USA.
Annals of the New York Academy of Sciences
|February 8, 2006
Summary
Gene therapy using CD154-engineered leukemia cells reduced chronic lymphocytic leukemia (CLL) in patients. This approach activated T cells and enhanced apoptosis sensitivity in CLL cells, offering a promising new treatment avenue.
Area of Science:
- Immunology
- Oncology
- Gene Therapy
Background:
- Chronic lymphocytic leukemia (CLL) is a B-cell malignancy with limited treatment options.
- Current therapies often have significant side effects and may not achieve durable remissions.
Purpose of the Study:
- To evaluate the efficacy of autologous leukemia cells engineered to express recombinant CD154 (adenovirus-mediated) in patients with CLL.
- To investigate the immunological mechanisms underlying the therapeutic response, including T-cell activation and apoptosis induction in CLL cells.
Main Methods:
- Patients received a single infusion of autologous CLL cells genetically modified with adenovirus encoding CD154.
- Leukemia cell counts, lymph-node size, CD4+ T-cell responses, and serum cytokine levels (IL-12, IFN-gamma) were monitored.
- Apoptosis pathways, including expression of Bid, Fas, DR5, and apoptosis-related proteins, were analyzed in CLL cells post-treatment.
- The effect of X-linked inhibitor of apoptosis (XIAP) inhibitors on Fas-mediated apoptosis was assessed.
Main Results:
- A one-time infusion of CD154-transduced autologous CLL cells led to significant reductions in leukemia cell counts and lymph-node size.
- Treatment correlated with increased leukemia-specific CD4+ T cells and elevated serum IL-12 and IFN-gamma levels.
- CD40 ligation on CLL cells induced expression of proapoptotic molecules (Bid) and death receptors (Fas, DR5), altering apoptosis sensitivity.
- CLL cells initially resisted then became sensitive to Fas-mediated apoptosis, influenced by differential protein expression.
- XIAP inhibitors enhanced Fas-mediated apoptosis sensitivity in CD40-activated CLL cells, even at early time points.
Conclusions:
- CD154-based immune-gene therapy demonstrates potential for reducing leukemia burden and improving immune responses in CLL patients.
- The mechanism involves T-cell activation and modulation of apoptosis pathways in CLL cells.
- Combining CD154 therapy with XIAP inhibitors may represent a strategy to enhance treatment efficacy for B-cell malignancies.